metformin and cardiovascular (CV) risk
Last reviewed 03/2022
- a systematic review investigated the cardiovascular outcomes in trials of
oral diabetes drugs or placebo in type 2 diabetes
- treatment with metformin hydrochloride was associated with a decreased risk of cardiovascular mortality (pooled OR, 0.74; 95% CI, 0.62-0.89) compared with any other oral diabetes agent or placebo; the results for cardiovascular morbidity and all-cause mortality were similar but not statistically significant
Reference: